Stuttgart - Delayed Quote EUR

Innovent Biologics, Inc. (6IB.SG)

Compare
4.9000
0.0000
(0.00%)
At close: March 3 at 8:56:17 AM GMT+1
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,206,070
6,206,070
4,556,380
4,269,729
3,843,819
Cost of Revenue
1,136,266
1,136,266
930,990
505,337
387,761
Gross Profit
5,069,804
5,069,804
3,625,390
3,764,392
3,456,058
Operating Expense
5,979,014
5,979,014
6,207,275
5,703,539
3,498,501
Operating Income
-909,210
-909,210
-2,581,885
-1,939,147
-42,443
Net Non Operating Interest Income Expense
354,213
354,213
87,839
89,291
47,752
Pretax Income
-1,144,411
-1,144,411
-2,170,469
-2,641,717
-858,713
Tax Provision
-116,498
-116,498
8,801
87,038
139,708
Net Income Common Stockholders
-1,027,913
-1,027,913
-2,179,270
-2,728,755
-998,421
Diluted NI Available to Com Stockholders
-1,027,913
-1,027,913
-2,179,270
-2,728,755
-998,421
Basic EPS
-0.66
--
-1.46
-1.88
-0.74
Diluted EPS
-0.66
--
-1.46
-1.88
-0.74
Basic Average Shares
1,559,637.0040
--
1,490,123.1920
1,455,605.7510
1,357,011.7570
Diluted Average Shares
1,559,637.0040
--
1,490,123.1920
1,455,605.7510
1,357,011.7570
Total Expenses
7,115,280
7,115,280
7,138,265
6,208,876
3,886,262
Net Income from Continuing & Discontinued Operation
-1,027,913
-1,027,913
-2,179,270
-2,728,755
-998,421
Normalized Income
-1,054,728.8403
-1,054,728.8403
-2,183,141.5000
-2,821,986
-1,020,753
Interest Income
452,837
452,837
189,537
151,755
116,102
Interest Expense
98,624
98,624
101,698
62,464
68,350
Net Interest Income
354,213
354,213
87,839
89,291
47,752
EBIT
-1,045,787
-1,045,787
-2,068,771
-2,579,253
-790,363
EBITDA
-660,684
-660,684
-1,749,349
-2,374,506
-704,736
Reconciled Cost of Revenue
1,136,266
1,136,266
930,990
505,337
387,761
Reconciled Depreciation
385,103
385,103
319,422
204,747
85,627
Net Income from Continuing Operation Net Minority Interest
-1,027,913
-1,027,913
-2,179,270
-2,728,755
-998,421
Total Unusual Items Excluding Goodwill
29,855
29,855
5,162
124,308
29,776
Total Unusual Items
29,855
29,855
5,162
124,308
29,776
Normalized EBITDA
-690,539
-690,539
-1,754,511
-2,498,814
-734,512
Tax Rate for Calcs
0.0001
0.0001
0.0003
0.0003
0.0003
Tax Effect of Unusual Items
3,039.1597
3,039.1597
1,290.5000
31,077
7,444
12/31/2020 - 11/7/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

196170.KQ ALTEOGEN Inc.
400,000.00
+3.36%
 
MGNX MacroGenics, Inc.
2.2800
-7.32%
 
IPA ImmunoPrecise Antibodies Ltd.
0.3292
-4.08%
 
DNA Ginkgo Bioworks Holdings, Inc.
8.01
-2.79%
 
VKTX Viking Therapeutics, Inc.
25.70
-10.98%
 
RXRX Recursion Pharmaceuticals, Inc.
6.59
-12.25%
 
MRNA Moderna, Inc.
30.27
-2.23%